Decibel Therapeutics to Present at the Association for Research in Otolaryngology (ARO) Conference

will showcase capabilities across its inner ear-focused
drug discovery and development platform at the 42nd annual
mid-winter meeting of the Association for Research in Otolaryngology
(ARO) from February 9-13, 2019. The data to be presented will
demonstrate new insights on the delivery of medicines to the inner ear
through multiple modalities, including gene therapy and biologics, as
well as the development of biomarkers, assays and tools to address
cochlear synaptopathy and other disorders.

This last year has been transformative for Decibel,” said Michael Su,
Ph.D., Decibel’s chief scientific officer. “Not only have we advanced
two compounds for the prevention of hearing loss into Phase I clinical
studies, but we’ve also strengthened our discovery and delivery
capabilities in support of our early stage pipeline programs in
monogenic hearing loss, tinnitus and balance. We’re looking forward to
sharing this broader suite of capabilities with our colleagues at ARO.”

The Decibel team will have a total of 11 presentations during the

Podium Presentations

Presidential Symposium 6 | Refinement of Age-related Hearing Loss
Patient Populations and Targeted Treatments

  • Presenter: Michael Su, Ph.D.
  • Session Title: Presidential Symposium
  • Date & Time: Saturday, February 9, 10:50a.m.

PD 42 | Vgf Expression is a Biomarker of NTF3 Target Engagement
in Mouse Spiral Ganglion Neurons In Vitro and In Vivo

  • Presenter: Joseph Burns, Ph.D.
  • Session Title: Intracochlear Drug Delivery & Biomarkers
  • Date & Time: Sunday, February 10, 2:15p.m.

PD 45 | Restoration of Hearing in Tmc1-Deficient Mice Depends on
Early and Well-Regulated Gene Delivery

  • Presenter: Adam Palermo, Ph.D.
  • Session Title: Intracochlear Drug Delivery & Biomarkers
  • Date & Time: Sunday, February 10, 3:00p.m.

PD 43 | Dual AAV Vectors for Delivery of Large Genes

  • Presenter: Theresa Abell, M.S.
  • Session Title: Intracochlear Drug Delivery & Biomarkers
  • Date & Time: Sunday, February 10, 2:30p.m.

Poster Presentations

PS 273 | Unbiased Classification of Audiometric Phenotypes in the
NHANES Database

PS 469 | In Vitro Characterization of Different AAV-Ntf3s
for Proof of Concept In Vivo Studies

PS 695 | A Single Cell Transcriptomic Characterization of the Stria
and Lateral Wall from the Adult Mouse Cochlea

PS 707 | Development of Robust In Vitro and Ex Vivo
Assays to Support Drug Discovery Programs

PS 708 | Distribution and Retention of Neurotrophin-3 in Cochlea

PS 709 | Functional Improvement and Target Engagement in Mouse
Model of Synaptopathy Following Sustained Exposure via AAV8-Ntf3 Delivery

PS 710 | Tropism of Engineered Serotypes in Adult Rodent Cochlea:
Towards Translationally Relevant Vectors

For further detail on Decibel’s presence at the conference, please visit
the Association for Research in Otolaryngology website at

About Decibel Therapeutics, Inc.
Decibel Therapeutics, a
clinical-stage biotechnology company, has established the world’s first
comprehensive drug discovery, development, and translational research
platform for hearing and balance disorders. Decibel’s lead therapeutic
candidates, DB-020 and DB-041, are designed to prevent hearing loss
resulting from cisplatin and aminoglycoside antibiotics, respectively.
Decibel is also advancing a portfolio of discovery-stage programs aimed
at restoring hearing and balance function to further our vision of a
world in which the benefits and joys of hearing are available to all.
Decibel is headquartered in Boston, Mass. For more information about
Decibel Therapeutics, please visit
or follow @DecibelTx on Twitter.


Sara Green, Ten Bridge Communications

error: Content is protected !!